Study removes AMR plasmids using a mobile, broad-host-range CRISPR-Cas9 delivery tool.
Santhera’s Agamree becomes first approved treatment in UK for all DMD patients – Pharmaceutical Technology
Share this article Santhera’s chief medical officer Shabir Hasham said the company is planning on making Agamree available in the UK in the second half